Parkinson's Disease Neuroprotection Clinical Trial

帕金森病神经保护临床试验

• 批准号: 6797238
• 负责人: JULIE H CARTER
• 金额: $ 2.61万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6797238
• 关键词: Parkinson' s disease; caregivers; chemoprevention; clinical research; clinical trials; cooperative study; family structure /dynamics; home health care; human subject; human therapy evaluation; medical outreach /case finding; nervous system disorder therapy; neuropharmacology; neuroprotectants; patient oriented research

DESCRIPTION (provided by applicant): The next quantum step forward in the treatment of Parkinson's disease will be the development of therapies which slow the progression of the disease. Testing of new agents will require recruitment of recently diagnosed Parkinson's disease subjects and retention of them in therapeutic trials lasting five to ten years. The extensive experience of the Oregon Health & Science University Parkinson Center of Oregon in conducting clinical trials, specifically long trials in recently diagnosed subjects, supports our inclusion in a cooperative multicenter trial of neruoprotective agents for Parkinson's disease. We also propose a number of means by which we may increase enrollment of de novo subjects, including subjects from minority groups, and retain them in the study. In addition, long-term trials of neuroprotective agents in early Parkinson's disease offer a unique opportunity to study the natural history of family care giving, assess caregiver strain as an outcome variable for new therapeutics and identify potential interventions to reduce care giving strain. These studies will extend and expand the preliminary studies of family care giving in Parkinson's disease we have done in the Parkinson Study Group DATATOP cohort.

描述（由申请人提供）：帕金森病治疗的下一个重大进展将是开发减缓疾病进展的疗法。新药的测试需要招募最近诊断出的帕金森病受试者，并将他们保留在持续五到十年的治疗试验中。俄勒冈健康与科学大学帕金森中心在进行临床试验，特别是在最近诊断的受试者中进行长期试验方面拥有丰富的经验，支持我们将其纳入针对帕金森病的神经保护剂的合作多中心试验。我们还提出了一些方法，可以增加新受试者（包括少数群体受试者）的入学率，并将他们保留在研究中。 此外，早期帕金森病神经保护剂的长期试验提供了一个独特的机会来研究家庭护理的自然史，评估护理人员的压力作为新疗法的结果变量，并确定减少护理压力的潜在干预措施。这些研究将延伸和扩大我们在帕金森研究组 DATATOP 队列中所做的帕金森病家庭护理的初步研究。